Due to supply chain concerns and the ongoing rapid rise in COVID-19 cases in the United States, the U.S. Department of Health and Human Services says it is moving to a weekly allocation cycle for related therapeutics for 3 weeks, starting January 3. HHS says it has stopped allocating bam/ete or Regen-COV to jurisdictions with 80% or more prevalence of the Omicron variant, given that data from the Centers for Disease Control and Prevention indicate that sotrovimab is the only therapy shown to be effective against that variant. An updated table showing distribution by state is available here. For more details, consult HHS’s Updated Guidelines Regarding Allocation of Bamlanivimab/Etesevimab and REGEN-COV Therapeutics States and Territories.
What You Need to Know About the Efficacy—and Availability—of COVID-19 Therapeutics